All aminoglycosides are produced by soil actinomycetes. All are bactericidal and
        more active at alkaline pH.
    
    The amoniglycosides are bactericidal antibiotics all having same properties.
    
        - Transport of the aminoglycosides through the bacterial cell wall and cytoplasmic
            membrane
 
        - Binding to ribosome resulting in inhibition of protein synthesis. 
 
        - The cidal action is based on secondary changes in the integrity of bacterial cell
            membrane .
 
    
    
    
        - Avoid during pregnancy.
 
        - Avoid concurrent use of other ototoxic, nephrotoxic drugs.
 
        - Cautious use in patients past middle age and those with kidney damage.
 
        - Cautious use of muscle relaxants in patients receiving aminoglycosides. 
 
        - Do not mix any other drug with aminoglycoside in the same syringe. 
 
    
    
    
        - Ototoxicity.
 
        - Nephrotoxicity.
 
        - Neuromuscular blockade.
 
    
    
    Commercial name: S 0.75gm, 1gm vial.
    
    
        - Tuberculosis.
 
        - Sub-acute bacterial endocarditis.
 
        - Plague.
 
        - Tulareamia.
 
    
    
    
        - Topical use is contraindicated for fear of contact sensitization.
 
    
    
    
        - Rashes, eosinophilia, fever and exfoliative dermatitis are noticed.
 
        - Hypersensitivity is rare.
 
        - Pain at injection site.
 
        - Paraesthsia and scotoma are occasional.
 
    
    
    
        Commercial name: Garamycin, Gentasporin, Genticyn 20,60, 80, 240 mg/vial inj; also
        0.3% eye/ ear drops, 0.1 % skin cream.
    
    
    
        - Preventing and treating respiratory infections in critically ill patients, in those
            with impaired host defence.
 
        - Pseudomonas, Proteus or Klebsiella infections in critically ill patients.
 
        - Meningitis caused by gram-ve bacilli. 
 
        - Dosage: For average adult with normal renal clearance 3-5mg/kg/day I.M. either single
            dose or divided in 3 or 8 hourly doses. 
 
    
    
    
        - Risk of toxicity is greater with impaired renal function, high dosage or prolonged
            therapy.
 
        - Avoid concurrent and/or sequential topical and /or systematic use of other potential
            neurotoxic and/or nephrotoxic drugs. 
 
        - W/P: Nueromuscular blockade, respiratory paralysis, ototoxicity and nephrotoxicity
            may occur.
 
    
    
    
        Commercial name: Tobacin 20, 60, 80mg in 2ml inj; 0.3% eye drops, Tobraneg 
        20, 40, 80mg per 2ml vial inj.
    
    
    
        - Serious infections caused by Pseudomonas and Proteus. 
 
    
    
    
        - Caution with muscular disorders and renal, auditory, vestibular or neuromuscular
            disorders. 
 
    
    
    
        - Voice alteration, taste perversion and tinnitus.